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ABSTRACT
There is evidence abroad of a cautious if not protective 
approach to research involving children and young 
people (CYP). We are sensitive to these views but 
believe they are based on a misconception that we must 
address together. In this introductory article we look 
at the complexities and risks of this research, how we 
must involving CYP and their families in the all aspects 
of research, how to seek valid consent and assent and 
how research indings should be reported. Considering 
how we should conduct this ongoing debate, we outline 
seven principles that we believe should underpin the 
necessary dialogue between all with legitimate interest. 
Our debate should be: (1) evidence informed: arguments 
should be supported by appropriate and reasonably 
accurate factual claims; (2) transparent about the 
grounds for decisions; (3) balanced: arguments should be 
met by contrary arguments; (4) conscientious: we must 
be willing to talk and listen, with civility and respect; (5) 
substantive: arguments should be considered sincerely 
on their merits, not on how they are made or by who is 
making them; (6) comprehensive: all points of view held 
by signiicant portions of the population should receive 
attention; and (7) with procedures for revising decisions 
in light of challenges, and it should be our responsibility 
to ensure we have met all of these.
INTRODUCTION
As a reader of the Archives of Diseases in Child-
hood, you will most probably believe that research 
on the healthcare of neonates, children and young 
people (CYP) is a good thing. That it is practical 
to undertake, can be done ethically, effectively, 
and make meaningful differences to the well-being 
and survival of CYP with a range of disorders. 
There are some people who hold different views 
though. They are concerned and protective. It is 
not uncommon for people to be horrified of the 
idea of research being conducted on CYP, without 
a clear understanding of the nature of what clin-
ical research is, or entails. Examples of malfea-
sance receive prominent coverage to support this 
position. As evidenced in a recent survey, 58% of 
those asked thought CYP were not allowed to take 
part in research1 and even in early 2018, a major 
UK Children's Hospital received a horrified phone 
complaint from a member of the public who had 
learnt they were experimenting on children. The 
hospital was engaged in a large number of perfectly 
valid, ethical, approved clinical trials. Beyond this, 
pragmatic issues present a barrier to research. There 
are healthcare providers who believe research is 
valid and useful, but not practical or possible in 
their setting. Even those engaged in research may 
be restricting access based on their mistaken beliefs 
around protecting families.2 We understand and are 
sensitive to these views but believe they are based 
on a misconception that fails to recognise the dual 
vulnerability of CYPto possible research harm, 
yes, but more widely and more commonly with 
much consequent harm, to unresearched care. How 
do we present our case to such audiences? This first 
article in our series offers an insight into some of 
the complexities of undertaking research with CYP, 
how we can move forward and how we can work 
together to ensure a better understanding of the 
need to involve CYP in health research.
COMPLEXITIES OF INVOLVING CYP IN 
RESEARCH
The argument for involving CYP in research can be 
found all around us. The thirst for answers to the 
broad common questions of How do I diagnose 
this?, How do I treat this?, What caused this? 
and What is the likely outcome of this? echoes 
nearly every month in the Archimedes section of 
this journal.3 These questions outline the first pair 
of our beliefs: Care not informed by good quality 
evidence can be dangerous; though good quality 
evidence that is not implemented into practice is 
wasteful and can be just as dangerous. Poor quality 
research can harm CYP for years after publication,4 
and it is obvious poor quality research is a risk to 
whomever it is undertaken on.
Exploring risks and differences
The first step is to explore this double vulnerability 
of CYP in research: we need to find the balance 
between the risks of research against the risks of care 
based on treatment which have not been subject to 
research. Studies which seek to trial new approaches 
which are genuinely felt to offer benefits may, in 
testing, fail to provide a better treatment than the 
ones which exist. Exposing CYP, particularly those 
with ill health to this risk could be considered unfair 
and unethical. However, the competing risk of not 
advancing therapies, or by acting on 'best guess' and 
pathophysiology, may produce the same results as 
the prone sleeping advice of previous decades.5
Historically, a solution used to address this risk is 
to test new drugs and interventions in adults, rather 
than CYP, before modifying the doses for CYP on the 
basis of understanding the pharmacology. However, 
this implies that the only thing that differs between 
CYP and adults is drug handling. While this is some-
times the case, it is not always; an apparently similar 
condition, such as acute lymphoblastic leukaemia, 
may have hugely different pathological mecha-
nisms in a 3 month-old, 2 year-old, 15 year-old and 
50 year-old.6 This example reinforces the necessity 
to consider undertaking research with CYP.
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Historical events can sometimes add to the difficulties faced. 
There have been mistakes and malpractice in research involving 
CYP, including the retention of organs without consent,7 and 
inaccurate reporting which has caused unnecessary suspicion.8 
While we cannot change the course of history or the views of 
the entire population, we can make sure we own up to these 
mistakes and commit to research integrity, and that we seek 
every chance to explain the need for CYPs research and what it 
actually means.
Gaining informed consent and assent
Even if a need for CYPs research is accepted and is deemed 
safe, there may be anxieties around CYP being unable to give 
informed consent. However, this can and should be considered in 
the same way any other medical procedure would be undertaken 
in standard clinical care; consent should be sought from a legal 
guardian who acts in the best interests of CYP to make a consid-
ered decision about the choices offered, for example, parents 
and carers. A neonate cannot consent to surgery for volvulus, 
nor can an infant with retinoblastoma for radiotherapy, but both 
occur ethically. The same challenges are present in adults who do 
not have the capacity to consent for themselves, but this group 
too deserves access to appropriate research studies. The process 
of gaining informed consent needs to be age and developmen-
tally appropriate, and assent should at least be sought from 
CYP who are able to communicate with adult professionals, in 
addition to consent from the legal guardian. Where viable, it is 
essential that CYP have a say in whether or not they wish to 
take part in researcha voice which cannot be ignored. In addi-
tion, gaining informed consent and assent should not be viewed 
as a solitary event; rather, it should be viewed as a continuous 
process involving mutual discussion and observations of both 
verbal and non-verbal signs of satisfaction with the research.
Involving CYP and their families in the design of research
Beyond including CYP as participants in research, the studies 
themselves need to have been designed from the earliest oppor-
tunity with CYP living with the condition, as well as their 
families in a patient and public involvement and engagement 
(PPIE) capacity, complementing the other relevant stakeholders 
involved in the design and conduct of the research. The views 
of what is the problem, what is acceptable to be treated with 
and how to undertake and evaluate research may differ mark-
edly between researchers and CYP and their families; therefore, 
it is fundamental that everyone is involved meaningfully in the 
research process.9 How to make engagement meaningful, more 
than the tick box experiences of some families from the past, 
we describe in forthcoming papers.
Transparent reporting of research findings
Beyond undertaking good quality research, the community 
needs to share it effectively and honestlyto both professional 
and public audiences. There is a wealth of literature published 
about the dangers of not reporting research findings.10 11 If 
research is not reported, we cannot get a fair and representa-
tive view of what the true answers to clinical questions are. As 
a consequence, we are left unsure, meaning that trials may be 
unnecessarily conducted with an ineffective intervention given 
to participantsor worse, skewed by selective publications, 
pouring resources and exposing patients to an intervention 
which does not work as well as we believe.
Even if research is reported, it needs to be reported clearly. 
This allows a fair assessment of the risks of biases to be made, 
and so an appreciation of its possible value in practice. Using an 
agreed structured report format ensures that the research which 
is undertaken is described clearly with all the key elements. These 
guides have been developed for a large number of study designs 
answering different clinical questions and are collected on the 
Enhancing the Quality and Transparency of Health Research 
Network website.12 A very well-known type of reporting guide-
line is the Consolidated Standards of Reporting Trials checklist; 
this sets out a minimum standard and list of items which need to 
be included in the reports of randomised clinical trials. Similar 
guidelines exist for systematic reviews (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses), observational 
studies (Strengthening the Reporting of Observational Studies 
in Epidemiology) and even animal preclinical studies (Animal 
Research: Reporting of In Vivo Experiments). If the ethical 
imperative does not encourage individuals to adhere to these 
reporting guidelines, the mandating of the correct approach 
being followed by major journals, including the ADC, ultimately 
may force individuals into doing the right thing anyways.
Traditional reporting of research in journals is barely adequate 
for dissemination of findings to academic professionals, but 
remain necessary for quality of research assessments in higher 
education, for example, the UK Research Excellence Frame-
work.13 Journal articles are largely inaccessible to the general 
public, even if research is published open access. The research 
community needs to engage with clinicians and the public in 
explaining and sharing its research. Public engagement, as part 
of a PPIE strategy, should be planned at the earliest opportunity 
of any given piece of research, if the community is to truly make 
research accessible for all. Vibrant approaches can be found in 
many places, for example, the picnics and portraits of the Born 
In Bradford cohort study.14
HOW THEN TO MOVE FORWARD?
Research will only succeed if it is a true partnership involving 
those with legitimate interest. CYP (and all patients and public 
in general) should be active partners in research, with their views 
sought when relevant. Their involvement should map across the 
entire research process, including prioritisation, design, conduct 
and dissemination of research. As with other research methods, 
it should be a subject of research itself to determine its value and 
improve its contribution. We also need to actively recognise that 
clinical delivery of care may differ from the clinical researchers 
undertaking studies; this practical aspect of making research 
work for people needs addressing. How then might we develop 
and conduct these partnerships successfully? This needs us to:
1. Identify all stakeholders with a legitimate interest.
2. Then engage with all stakeholders in fair debate.
CYP and families who have the health conditions under study 
will most likely share the professionals view that research is of 
benefit. They are likely to be research friendly and are often 
the champions of promoting research and the need for funding, 
encompassing the entire spectrum of prioritisation through to 
dissemination and further priority setting. The practicalities of 
how this can work will be explored further in a later paper, but 
in summary, include ongoing CYP research advocacy groups like 
Generation R15; specific prioritisation project groups, such as 
condition-relevant James Lind Alliance Priority Setting Partner-
ships16; and project-based groups like the BRIGHTLIGHT study 
Youth Advisory Panel.17
However, the emotional aspects of engaging and involving 
CYP and their families in research can be underestimated. Fami-
lies, especially those whose CYP are currently in good health, are 
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likely to more cautious in their approach, but there is support 
available. In a recent survey conducted by the Health Research 
Authority (HRA), 83% of members of the public said that health 
research is important.1 Focus group discussions have demon-
strated that a major reason for caution is misunderstanding of 
the place and risks of research (HRA unpublished information). 
They are likely to share the view that research and care are sepa-
rate activities, and should remain so.
To work with these concerns requires us to have an emotional 
understanding of research, while following some practical guid-
ance. The UK has worked extensively in this area and can provide 
clear examples and guidance, such as through the National Insti-
tute for Health Research INVOLVE organisation, who provide 
further guidance on PPIE in research. Furthermore, a detailed 
report on the ethical elements to be considered with research 
can be enlightening.18
When research into research is examined, it is found clinical 
teams, while likely to voice statements supportive to the concept 
of research, can often find good reasons why it cannot be under-
taken in their area or these particular cases.19 This may be a 
simple resource-stretch, emotional and mental overload of Too 
much to do; research is imperative but providing clinical care 
for CYP is more important.
Work from Professor Bridget Young at the University of Liver-
pool demonstrated that professionals are more of a barrier than 
patients.2 Despite saying little during trial discussions, parents 
described feeling comfortable and involved and they valued the 
way that practitioners explained the trials, but practitioners were 
often concerned that families were overwhelmed with infor-
mation. When the parents were asked about this, they did not 
object to being asked about trials and many positively wanted to 
be approached.
Parents were more positive about being approached to enter their 
child into a clinical trial than practitioners anticipated. The con-
cerns of some practitioners, that parents would be overburdened, 
were unfounded. Educating practitioners about how families per-
ceive clinical trials and providing them with moral support in ap-
proaching families may benefit paediatric research and, ultimately, 
patients.
Our inclusion of trials that recruited children who were severely or 
critically ill has confirmed that recruitment to such trials is more 
challenging for both parties. However, even in these circumstanc-
es, parents did not construe the trial approach as an unwelcome 
burden.
If you add to this some bad apple stories of when the expe-
rience of healthcare professionals of research being unwieldy, 
impractical and unusable in the 'real world' of clinical practice 
along with ethical knots that may be tied20 there is a chunky 
barrier to overcome. It can be possible thoughand there are 
several examples to demonstrate that it is practical. We would 
point to the example of children's haematology and oncology to 
show a specialty that was born with an integration of trials into 
everyday practice and continues to advance care through many 
different studies.21 This may be considered a golden bubble with 
the media, researchers and patients all with a heightened aware-
ness of the need for research. Other parts of paediatrics have 
shown similar success though, with a range of huge neonatal 
trials undertaken across very large numbers of centres22 23 and 
the explosion of productive research networks, like Pediatric 
Emergency Research in the UK and Ireland in paediatric emer-
gency care, which has demonstrated that emergency and acute 
paediatrics can be research active24 in the same fashion as their 
subspecialist or critical care cousins. Children's palliative and 
end of life care is not a research-free zone either, with research 
hubs producing work developing this.25
Research needs regulators and ethical reviewers to sign off  
on studies. Historically, ethics research committees have been 
viewed as the cautious gatekeepers,26 focused on childrens 
status as vulnerable. This is not often the case anymore, with 
regulators promoting a balanced approach, and valuing chil-
drens researchers becoming engaged with developing regula-
tion. An ethically conducted study is recognised as providing no 
or minimal risk to participants; that is, no greater than everyday 
life. This series goes on to advise how best to clearly think 
through and place the arguments for a smooth ethical review of 
your paediatric study, and the authors are working to develop 
resources and skills in the same zone for those sat on the other 
side of the table.
Moving forward can only occur with appropriate funding 
for research too. We are not delving deep into this aspect of 
making research happen, but agree with a strategy of planning to 
improve the quantity and quality of paediatric research, recog-
nising while a minority interest, creating happy and healthy 
children may have a significant impact on adult health and life-
course healthcare burden.27
THE FUTURE: AGREEING ON HOW TO WORK TOGETHER
The future will be brighter if we can bring these multiple stake-
holder groups, views and competing interests together. Consid-
ering how to proactively enter into discussions, and to do this 
fairly and honestly, we could consider two recent models in 
health and bioethicsDemocratic deliberation and Account-
ability for Reasonableness.2830
Democratic deliberation holds five principles:
1. Evidence informed: Arguments should be supported by ap-
propriate and reasonably accurate factual claims. Cherry 
picking facts and straw man-based arguments are polemical 
not honest.
2. Balanced: Arguments should be met by contrary arguments.
3. Conscientious: The participants should be willing to talk and 
listen, with civility and respect.
4. Substantive: Arguments should be considered sincerely on 
their merits, not on how they are made or by who is making 
them.
5. Comprehensive: All points of view held by significant por-
tions of the population should receive attention.
Accountability for Reasonableness, developed by Daniels and 
Sabin in the setting of managing fair distribution of a limited 
health resource, adds two further principles propose three 
elements of fair process:
1. Transparency about the grounds for decisions.
2. Procedures for revising decisions in light of challenges.
Together these approaches lead us to suggest that good research 
will build on the past, take alternative views and opinions into 
account, learn from errors and mistakes and work with changing 
systems to make research safer, more efficient and more rele-
vant. (See online supplementary appendix: Minor Carta.)
THE CONCLUSION
Engaging and undertaking research with CYP and their families 
can happen successfully. It takes detailed planning, enthusiasm, 
the application of resources, thinking, meaningful discussion, 
people skills, cake, a sprinkle of good luck and lots of effort 
but research can occur as part of real life clinical practice. It is 
unethical for it not to be an integral offering of modern, effective 
healthcare in the 21st century.
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